Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992285766> ?p ?o ?g. }
- W1992285766 endingPage "70" @default.
- W1992285766 startingPage "65" @default.
- W1992285766 abstract "Purpose: To report the survival results from a previous Phase I study of etanidazole (ETA) and radiotherapy in patients with glioblastoma multiforme (GBM n = 50) or anaplastic astrocytoma (AA n = 19) and examine survival according to age, Karnofsky performance status (KPS), and implant status.Patients and Methods: In a previous Phase I study, 70 previously untreated patients (median age 49) with malignant gliomas were accrued. One patient was excluded from analysis because pathology was unverifiable. All had KPS ≥ 70. Prior to initiation of treatment, patients were stratified according to whether they were candidates for interstitial implantation. The implant patients (IMP n = 14) received accelerated fractionation radiotherapy (XRT) 2 Gy BID (6 hours apart) to 40 Gy in 2 weeks with ETA 2 gm/m2 × 6 doses, a 2 week break, and then interstitial implant for an additional 50 Gy (4–7 days) with a continuous infusion of ETA over 90–96 hours. There were 55 patients treated on two sequentially conducted non-implant arms. These patients started with accelerated fractionation XRT 2 Gy BID (6 hours apart) to 40 Gy in 2 weeks with ETA 2 gm/m2 × 4–5 doses/week. Non-IMP1 arm (n = 41) received a 2-week break before standard fractionated boost XRT of 2 Gy/day for 2 weeks to a total dose of 60 Gy with ETA. Non-IMP2 arm (n = 14) did not have the 2-week break. All patients had plasma pharmacokinetic monitoring of ETA. Subsequent follow-up study provided information regarding long-term survival status of this group of patients. The Phase I toxicity evaluation was conducted according to the RTOG toxicity scale and was found well tolerated in both groups. Overall actuarial survival was plotted for all patients, by histologic group, and by implant status. Subset analyses of GBM patients by age (≤ 49 or > 49 years), KPS (≤ 80 or > 80) and implant versus non-implant were also performed.Results: Median survival of GBM patients was 1.1 years and that of anaplastic astrocytoma patients was 3.1 years (p = 0.0001). In GBM patients, KPS > 80, implanted patients, and age ≤ 49 were factors found not to be associated with a statistically improved survival.Conclusion: The results of survival in this Phase I etanidazole study of patients with anaplastic astrocytoma are comparable to the results from other studies using bromodeoxyuridine, iododeoxyuridine, or procarbazine, lomustine (CCNU), and vincristine. The use of etanidazole with accelerated radiotherapy does not appear to improve survival in patients with glioblastoma multiforme compared to those treated with conventional therapies." @default.
- W1992285766 created "2016-06-24" @default.
- W1992285766 creator A5001528733 @default.
- W1992285766 creator A5021656597 @default.
- W1992285766 creator A5032667508 @default.
- W1992285766 creator A5059202876 @default.
- W1992285766 creator A5059890725 @default.
- W1992285766 creator A5070824167 @default.
- W1992285766 creator A5083728070 @default.
- W1992285766 date "1998-01-01" @default.
- W1992285766 modified "2023-10-16" @default.
- W1992285766 title "Survival Results from a Phase I Study of Etanidazole (SR2508) and Radiotherapy in Patients with Malignant Glioma" @default.
- W1992285766 cites W1603522466 @default.
- W1992285766 cites W1979300931 @default.
- W1992285766 cites W1994508894 @default.
- W1992285766 cites W2008825379 @default.
- W1992285766 cites W2036560693 @default.
- W1992285766 cites W2039704259 @default.
- W1992285766 cites W2042402866 @default.
- W1992285766 cites W2062398888 @default.
- W1992285766 cites W2066008137 @default.
- W1992285766 cites W2066734995 @default.
- W1992285766 cites W2076530554 @default.
- W1992285766 cites W2095002555 @default.
- W1992285766 cites W2111695740 @default.
- W1992285766 cites W2113012900 @default.
- W1992285766 cites W2139984188 @default.
- W1992285766 cites W2154121941 @default.
- W1992285766 cites W2163342290 @default.
- W1992285766 cites W2167836234 @default.
- W1992285766 cites W2168167387 @default.
- W1992285766 cites W2231666798 @default.
- W1992285766 doi "https://doi.org/10.1016/s0360-3016(97)00486-0" @default.
- W1992285766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9422559" @default.
- W1992285766 hasPublicationYear "1998" @default.
- W1992285766 type Work @default.
- W1992285766 sameAs 1992285766 @default.
- W1992285766 citedByCount "19" @default.
- W1992285766 countsByYear W19922857662018 @default.
- W1992285766 countsByYear W19922857662021 @default.
- W1992285766 countsByYear W19922857662022 @default.
- W1992285766 crossrefType "journal-article" @default.
- W1992285766 hasAuthorship W1992285766A5001528733 @default.
- W1992285766 hasAuthorship W1992285766A5021656597 @default.
- W1992285766 hasAuthorship W1992285766A5032667508 @default.
- W1992285766 hasAuthorship W1992285766A5059202876 @default.
- W1992285766 hasAuthorship W1992285766A5059890725 @default.
- W1992285766 hasAuthorship W1992285766A5070824167 @default.
- W1992285766 hasAuthorship W1992285766A5083728070 @default.
- W1992285766 hasBestOaLocation W19922857661 @default.
- W1992285766 hasConcept C126322002 @default.
- W1992285766 hasConcept C126894567 @default.
- W1992285766 hasConcept C141071460 @default.
- W1992285766 hasConcept C2776194525 @default.
- W1992285766 hasConcept C2776694085 @default.
- W1992285766 hasConcept C2776755627 @default.
- W1992285766 hasConcept C2778227246 @default.
- W1992285766 hasConcept C2778880634 @default.
- W1992285766 hasConcept C2779083369 @default.
- W1992285766 hasConcept C2779112685 @default.
- W1992285766 hasConcept C2779429289 @default.
- W1992285766 hasConcept C2781411149 @default.
- W1992285766 hasConcept C29730261 @default.
- W1992285766 hasConcept C2989005 @default.
- W1992285766 hasConcept C502942594 @default.
- W1992285766 hasConcept C509974204 @default.
- W1992285766 hasConcept C71924100 @default.
- W1992285766 hasConceptScore W1992285766C126322002 @default.
- W1992285766 hasConceptScore W1992285766C126894567 @default.
- W1992285766 hasConceptScore W1992285766C141071460 @default.
- W1992285766 hasConceptScore W1992285766C2776194525 @default.
- W1992285766 hasConceptScore W1992285766C2776694085 @default.
- W1992285766 hasConceptScore W1992285766C2776755627 @default.
- W1992285766 hasConceptScore W1992285766C2778227246 @default.
- W1992285766 hasConceptScore W1992285766C2778880634 @default.
- W1992285766 hasConceptScore W1992285766C2779083369 @default.
- W1992285766 hasConceptScore W1992285766C2779112685 @default.
- W1992285766 hasConceptScore W1992285766C2779429289 @default.
- W1992285766 hasConceptScore W1992285766C2781411149 @default.
- W1992285766 hasConceptScore W1992285766C29730261 @default.
- W1992285766 hasConceptScore W1992285766C2989005 @default.
- W1992285766 hasConceptScore W1992285766C502942594 @default.
- W1992285766 hasConceptScore W1992285766C509974204 @default.
- W1992285766 hasConceptScore W1992285766C71924100 @default.
- W1992285766 hasIssue "1" @default.
- W1992285766 hasLocation W19922857661 @default.
- W1992285766 hasLocation W19922857662 @default.
- W1992285766 hasOpenAccess W1992285766 @default.
- W1992285766 hasPrimaryLocation W19922857661 @default.
- W1992285766 hasRelatedWork W1982280388 @default.
- W1992285766 hasRelatedWork W2031477727 @default.
- W1992285766 hasRelatedWork W2042681244 @default.
- W1992285766 hasRelatedWork W2058747986 @default.
- W1992285766 hasRelatedWork W2132757537 @default.
- W1992285766 hasRelatedWork W2158789712 @default.
- W1992285766 hasRelatedWork W2327393891 @default.
- W1992285766 hasRelatedWork W2431855950 @default.
- W1992285766 hasRelatedWork W2460377520 @default.